{"Clinical Trial ID": "NCT00451555", "Intervention": ["INTERVENTION 1:", "Enzastaurin + Fulvestrant QD + BID", "The participants received a loading dose of 1125 mg Enzastaurin on the first day of Cycle 1 and then 500 mg oral (QD) once daily in a 28-day cycle.", "Participants received an enzastaurine loading dose of 1125 mg on the first day of Cycle 1 and an Enzastaurine oral dose of 250 mg (BID) twice daily in a 28-day cycle.", "Fluvestrant was administered intramuscularly at a loading dose of 500 mg on day 1 and 250 mg on day 15 in cycle 1. Subsequent doses of Fluvestrant of 250 mg were administered on day 1 of cycle 2 and every 28 days thereafter.", "...................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................", "INTERVENTION 2:", "Enzastaurin + BID Fulvestrant", "Participants received enzastaurine (250 mg; 2 tablets) or oral placebo twice daily (IDB) in a 28-day cycle until disease progression."], "Eligibility": ["Incorporation criteria:", "The primary or metastatic tumour should be the response to estrogen (ER) and/or the positive parathyroid hormone (PtR) receptor.", "Note: The positivity of hormone receptors is defined as ER or PtR greater than 10 fmol/mg by biochemical test or 10% by immunohistochemistry", "Participants are resistant to the treatment of aromatase inhibitors (AI)", "Women with postmenopausal status", "Previous radiation therapy is allowed, but should have been limited.", "A measurable or non-measurable disease", "Have a performance of 0, 1, or 2 on the scale of the Eastern Cooperative Oncology Group (ECOG)", "To have an adequate organ function", "Have an estimated life expectancy of at least 24 weeks", "\u2022 Must sign an informed consent document", "- Exclusion criteria:", "Has already been treated with fulvestrant or enzastaurine", "They are given concomitantly with any other antitumour therapy, with the exception of gonadotropin hormone antagonists (GnRH).", "\u2022 Has received treatment in the last 4 weeks with a drug that has not received regulatory approval for an indication at the time of entry into the study", "Did receive an estrogen or progesterone supplement within 4 weeks of entry into the study", "Are estrogen receptor hormone (HER2)-positive", "Not able to stop the use of anticoagulants", "\u2022 Have hypercalcaemia", "Have a second primary malignancy that is clinically detectable at the time of consideration for inclusion in the study", "Central nervous system (CNS) metastases, symptomatic pulmonary lymphangitis or more than one third of the liver have been documented.", "Have a serious concomitant systemic disorder", "Have a serious heart disease", "Are unwilling or unable to stop the use of carbamazepine, phenobarbital or phenytoin at least 14 days prior to study treatment", "Are unable to swallow the tablets."], "Results": ["Performance measures:", "Percentage of participants with the best complete response, partial response and stable disease (CR+PR+SD) response (clinical benefit rate)", "The rate of clinical benefit is defined as the rate of confirmed CR, confirmed PR and SD for 24 weeks and is the best response CR, PR or SD according to the researchers according to RECIST v1.1. CR is a disappearance of all target and non-target lesions and normalization of the level of tumour marker. PR is a decrease of at least 30% of the sum of the diameters of the target lesions (using the diameter of the reference sum as a reference) without progression of the non-target lesions or the appearance of new lesions. SD is not a shrinkage sufficient to be eligible for PR nor an increase sufficient to be eligible for progressive disease, taking as a reference the diameter of the smallest sum since the beginning of treatment.", "Time frame: Baseline data for measuring progressive disease or cessation of study (up to 24 weeks)", "Results 1:", "Title of the arm/group: Enzastaurin + Fulvestant QD + BID", "Description of the arm/group: Participants received an Enzastaurin loading dose of 1125 mg on the first day of Cycle 1 and only 500 mg orally (QD) once daily in a 28-day cycle.", "Participants received an enzastaurine loading dose of 1125 mg on the first day of Cycle 1 and an Enzastaurine oral dose of 250 mg (BID) twice daily in a 28-day cycle.", "Fluvestrant was administered intramuscularly at a loading dose of 500 mg on day 1 and 250 mg on day 15 in cycle 1. Subsequent doses of Fluvestrant of 250 mg were administered on day 1 of cycle 2 and every 28 days thereafter.", "...................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................", "Total number of participants analysed: 94", "Type of measurement: Number", "Unit of measure: percentage of participants 43.6 (33.4 to 54.2)", "Results 2:", "Title of the arm/group: Enzastaurin + BID Fulvestrant", "Description of the arm/group: Participants received enzastaurine (250 mg; 2 tablets) or oral placebo twice daily (IDB) in a 28-day cycle until disease progression.", "Total number of participants analysed: 39", "Type of measurement: Number", "Unit of measure: percentage of participants 43.6 (27.8-60.4)"], "Adverse Events": ["Undesirable Events 1:", "Total: 17/94 (18.09 per cent)", "Anemia 2/94 (2.13 per cent)", "- Lymphadenopathy 0/94 (0.00 %)", "Angine pectoris 0/94 (0.00 %)", "Ischemic cardiomyopathy 0/94 (0.00 %)", "Myocardial infarction 1/94 (1.06%)", "Hemorrhoids 1/94 (1.06%)", "Ileus 1/94 (1.06%)", "Nausea 1/94 (1.06%)", "1/94 (1.06 %)", "Asthenia 1/94 (1.06%)", "Rate of disease progression 0/94 (0.00 %)", "Peripheral edema 1/94 (1.06%)", "Adverse Events 2:", "Total: 9/39 (23.08 per cent)", "Anemia 2/39 (5.13%)", "- Lymphadenopathy 0/39 (0.00 %)", "Angine pectoris 0/39 (0.00 %)", "Ischemic cardiomyopathy 0/39 (0.00 %)", "Myocardial infarction 1/39 (2.56 per cent)", "Hemorrhoids 1/39 (2.56%)", "Ileus 1/39 (2.56%)", "Nausea 1/39 (2.56%)", "Vomiting 1/39 (2.56 per cent)", "Asthenia 1/39 (2.56%)", "\u2022 Disease progression 0/39 (0.00 %)", "Peripheral edema 1/39 (2.56%)"]}